Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 1.00 |
| ▸ | MAOB | P27338 | 19/20 | 1.00 |
| ▸ | MAOA | P21397 | 13/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12242308 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL1287580 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL2340542 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL18691238 | 0.90 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL12242316 | 0.90 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL19092432 | 0.90 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL30283380 | 0.90 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL18691239 | 0.90 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL2337981 | 0.90 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL12242302 | 0.90 | KDM1A (1.00) | KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361242-B1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS SA (ES) | 2018-08-01 | — | — | EP | disclosed |
| US-8524717-B2 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263604-A1 | Oxidase inhibitors and their use | MAOA, PNPO, MAOB | KDM1A 920/4885MAOB 3/4885MAOA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.